BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Information Letter on SGLT2 inhibitors: Updated information on the risk of diabetic ketoacidosis

2016.03.14

Active substance: canagliflozin, dapagliflozin, empagliflozin

After completion of the European safety review by the CHMP, the pharmaceutical entrepreneurs concerned are circulating information on the recommendation to minimise the risk of diabetic ketoacidosis.

SGLT2 inhibitors

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 192KB, File is accessible